Light & Wonder, Inc. ("Light & Wonder," "L&W," "we" or the "Company") is providing an update on today's ruling from the Nevada Court regarding the ongoing litigation with Aristocrat. The Nevada Court ...
Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming ...
Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback